162 related articles for article (PubMed ID: 1488323)
1. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
[TBL] [Abstract][Full Text] [Related]
2. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
3. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin treatment improves platelet function in uremic patients.
Cases A; Escolar G; Reverter JC; Ordinas A; Lopez-Pedret J; Revert L; Castillo R
Kidney Int; 1992 Sep; 42(3):668-72. PubMed ID: 1405344
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and uremic platelet aggregation in vivo and in vitro.
Malyszko JS; Malyszko J; Pawlak K; Mysliwiec M
Int J Clin Lab Res; 1996; 26(3):199-202. PubMed ID: 8905452
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
[TBL] [Abstract][Full Text] [Related]
7. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy.
Caravaca F; López-Minguez JR; Arrobas M; Cubero J; Pizarro JL; Cid MC; Sanchez-Casado E; Miranda MP
Nephrol Dial Transplant; 1995; 10(9):1720-4. PubMed ID: 8559495
[TBL] [Abstract][Full Text] [Related]
8. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
[TBL] [Abstract][Full Text] [Related]
9. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin.
Moia M; Mannucci PM; Vizzotto L; Casati S; Cattaneo M; Ponticelli C
Lancet; 1987 Nov; 2(8570):1227-9. PubMed ID: 2890852
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin.
Zirkman DM; Zeigler ZR; Fraley DS; Bruns FJ; Adler S
Am J Kidney Dis; 1993 Jan; 21(1):31-7. PubMed ID: 8418623
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
el-Shahawy MA; Francis R; Akmal M; Massry SG
Clin Nephrol; 1994 May; 41(5):308-13. PubMed ID: 8050212
[TBL] [Abstract][Full Text] [Related]
13. [Effect of human recombinant erythropoietin (rhuEPO) on platelet phospholipids in chronically hemodialysed].
Krawczyk W; Dmoszyńska A; Ledwozyw A; Soroka-Wojtaszko M
Acta Haematol Pol; 1993; 24(4):327-31. PubMed ID: 8303978
[TBL] [Abstract][Full Text] [Related]
14. Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients.
Krawczyk W; Dmoszyńska A; Marczewski K; Ledwozyw A
Exp Nephrol; 1995; 3(4):265-6. PubMed ID: 8590040
[TBL] [Abstract][Full Text] [Related]
15. [Platelet aggregation and P-selectin concentration in patients on peritoneal dialysis treated with erythropoietin].
Małyszko J; Suchowierska E; Pawlak K; Małyszko JS; Myśliwiec M
Pol Arch Med Wewn; 2001 Mar; 105(3):197-201. PubMed ID: 11680263
[TBL] [Abstract][Full Text] [Related]
16. Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis.
Fabris F; Cordiano I; Randi ML; Casonato A; Montini G; Zacchello G; Girolami A
Pediatr Nephrol; 1991 Mar; 5(2):225-8. PubMed ID: 2031840
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
[TBL] [Abstract][Full Text] [Related]
18. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
19. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
20. One-year experience of very low doses of subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis and its effect on haemostasis.
Huraib S; Gader AM; al-Momen AK; Abu-Aisha H; al-Wakeel J; Memon NA
Haemostasis; 1995; 25(6):299-304. PubMed ID: 8586321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
